ClinicalTrials.gg
RecruitingNCT04420702Updated Nov 9, 2026

Diffusion Basis Spectrum Imaging of the Prostate

An interventional study of MRI with DBSI analysis in Prostate Cancer, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2020, registered Jun 2020).
  • Started Feb 2020; still recruiting 6 years 8 months later.
Updated Nov 9, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.

Planned enrollment
2nd of 20
500 · median 35
Started
2020
with 1 other
No phase
12 of 23
4 open now
Primary completion
2027-05
later than 2 of 10 live
Registered
13th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one is the 2nd largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2020, is one of 12 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 13th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years of age and willing and able to provide .
  • Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate as clinical standard of care ("early detection cohort")
  • Including those men with:

    • an elevated PSA and no prior biopsy
    • an elevated PSA and a negative prior biopsy
  • Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

Exclusion criteria

Exclusion Criteria:

  • Patients with any clinical to MRI

    *Including but not limited to:

    • Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
    • Those with cochlear implants
    • Those with claustrophobia not relieved with medications (patients with claustrophobia who do not need medications for the scan or whose claustrophobia can be managed with medication, are eligible to participate)
    • Those who cannot lie flat for over 1 hour
  • Patients with prior prostate surgery for prostate cancer (e.g. radical prostatectomy, focal ablation)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Early Detection Cohort (MRI with DBSI)

    * Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy * Standard of care prostate biopsy will be performed within 12 weeks of MRI * Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging

    Device: MRI with DBSI analysis

  • Experimental
    Active Surveillance Cohort (MRI with DBSI)

    * Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy * Standard of care prostate biopsy will be performed within 12 weeks of MRI * Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging

    Device: MRI with DBSI analysis

Interventions

  • DeviceMRI with DBSI analysis

    -The procedure will take approximately 1 hour of the participant's time

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) comparison from biopsy and DBSI

    * As a per patient analysis, the investigators will use the highest Gleason score from the biopsy as the reference standard * In the per patient analysis, Gleason 7 or greater, will be the cut-off as this will be considered "clinically significant". The investigators will also perform similar analyses with cut-offs of Gleason 4+3=7 or greater, as well as Gleason 6 or greater. This will serve as the sensitivity analysis.

    Time frame: Up to 12 weeks

  2. Receiver operating characteristic (ROC) comparison from biopsy to DBSI

    * As a per patient analysis, the investigators will use the highest Gleason score from the biopsy as the reference standard * In the per patient analysis, Gleason 7 or greater, will be the cut-off as this will be considered "clinically significant". The investigators will also perform similar analyses with cut-offs of Gleason 4+3=7 or greater, as well as Gleason 6 or greater. This will serve as the sensitivity analysis.

    Time frame: Up to 12 weeks

  3. Prostate sector analysis as measured by comparison of the highest Gleason score from each of the 10 biopsy sectors to the DBSI predicted pathology from each sector

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Comparison of Gleason score from the MRI regions of interest to the DBSI predicted pathology

    -Only for those patients with a suspicious MRI lesion

    Time frame: Up to 12 weeks

  2. Area under the curve (AUC) comparison from DBSI to conventional MRI interpretation

    Time frame: Up to 12 weeks

  3. Receiver operating characteristic (ROC) comparison from DBSI to conventional MRI interpretation

    Time frame: Up to 12 weeks

  4. Compare DBSI with the advanced restriction spectrum imaging (RSI)

    The investigators will perform DBSI modeling on RSI data obtained from UCSD and the results from both DBSI and RSI protocols will be compared and analyzed to determine a strategy for improving the DBSI protocol.

    Time frame: Up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Hongyu An, M.D., Ph.D. · Contacthongyuan@wustl.edu · 314-362-5805
    • Alex Kim · Contactklima@wustl.edu · 314-747-9781
    • Hongyu An, M.D., Ph.D. · Principal investigator
    • Sheng-Kwei Song, Ph.D. · Sub investigator
    • Michael H Johnson, M.D. · Sub investigator
    • Joseph Ippolito, M.D. · Sub investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for May 2027, 87 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 87 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 9, 2020
StartActual
Feb 27, 2020
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: i•••@wustl.edu · •••2925→h•••@wustl.edu · •••5805. See the current contact
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Washington University School of Medicine · St Louis, United StatesContact i•••@wustl.edu · •••2928→h•••@wustl.edu · •••5805Contact person changed (no phone or email listed)Contact added (no phone or email listed)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Contact Study contact changed: i•••@wustl.edu · •••2925→h•••@wustl.edu · •••5805. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Washington University School of Medicine · St Louis, United StatesContact i•••@wustl.edu · •••2928→h•••@wustl.edu · •••5805Contact person changed (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04420702
Collaborators
American Cancer Society, Inc., The Foundation for Barnes-Jewish Hospital, Midwest Stone Institute., National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Feb 27, 2020
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Hongyu An, M.D., Ph.D.
Contact
hongyuan@wustl.edu
314-362-5805
Alex Klim
Contact
klima@wustl.edu
314-747-9781
Hongyu An, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion